Investments, Funding & Disinvestment

The multi-target collaboration will integrate Insilico’s proprietary Pharma.AI platform with Bora’s automated manufacturing and development capabilities to establish a next-generation model for drug innovation.

The assistance forms part of a wider U.S.-Madagascar health partnership established under the bilateral Global Health Memorandum of Understanding (MOU) signed in December 2025.

Samsung Biologics is pursuing the acquisition as demand for peptide therapeutics continues to accelerate, particularly amid the global success of GLP-1 medicines for treating obesity and type 2 diabetes.

The signing ceremony brought together National Treasury and Economic Planning Cabinet Secretary John Mbadi, U.S. Chargé d’Affaires Susan Burns, Health Cabinet Secretary Aden Duale, senior government officials and representatives from both countries.

The launch includes eight hospital-grade hemodialysis concentrate solutions designed to support the treatment of patients living with kidney failure.

The transaction, announced on July 3, includes Tanabe Pharma Factory’s production facilities in Onoda and Yoshitomi.

Cambridge Health Saudi Arabia expects its licensed capacity to approach 500 beds once ongoing expansion projects at Cambridge Hospital Jeddah are completed and additional beds at Cambridge Hospital Dhahran receive regulatory approval.

The approval authorises the company to collect plasma in Indonesia and process it through its global manufacturing network while the country develops its own plasma infrastructure.

The investment package was launched in collaboration with the Ministry of Health and the Public Authority for Special Economic Zones and Free Zones.

The agreements were signed during a ceremony attended by senior government officials, including Bahrain’s Minister of Education, Dr Mohammed Mubarak Juma, and Saudi Fund for Development (SFD) Chief Executive Officer Sultan Al Marshad.